贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子的影响

doi:10.13699/j.cnki.1001-6821.2017.23.020

科研成果详情

题名	贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子的影响
其他题名	Effects of bevacizumab combined with cisplatin on immune function and vascular endothelial growth factors in the mice of Lewis lung cancer
作者	章展 1; 孙益青 2; 唐小万 1; 李文峰3
发表日期	2017-12-17
发表期刊	中国临床药理学杂志影响因子和分区
语种	中文
原始文献类型	学术期刊
关键词	贝伐单抗顺铂 Lewis肺癌小鼠免疫功能血管内皮生长因子
摘要	目的探讨贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子(VEGF)的影响。方法对SBF级健康BALB/c裸鼠右腋下注射处于对数生长期鼠源性Lewis肺癌细胞,建立肺癌小鼠模型。将造模成功的小鼠随机分为模型组、实验A组、实验B组和实验C组,每组8只;另取8只健康裸鼠作为对照组。模型组和对照组均给予腹腔注射0.9%Na Cl 0.4 m L,每周2次;实验A组给予腹腔注射15 mg·kg~(-1)贝伐单抗,每周2次;实验B组给予腹腔注射5 mg·kg~(-1)顺铂,每周2次;实验C组给予腹腔注射15 mg·kg~(-1)贝伐单抗和5 mg·kg~(-1)顺铂,每周2次。5组裸鼠均连续给药2周后处死,摘眼球取血和取瘤称重。比较5组裸鼠的抵瘤率、免疫功能、VEGF水平。结果治疗后,实验A,B,C组的抑瘤率分别为(46.57±5.45)%,(72.03±8.24)%和(87.47±9.02)%,任意2组比较,差异均有统计学意义(均P<0.05)。治疗后,对照组、模型组和实验A,B,C组的白细胞介素-2水平分别为(37.12±5.24),(15.24±2.36),(26.45±4.45),(7.36±1.02)和(22.32±3.25)pg·m L-1,白细胞介素-6水平分别为(125.36±15.24),(54.32±6.32),(86.45±10.12),(24.36±3.45)和(74.36±8.54)pg·m L-1,肿瘤坏死因子-α水平分别为(80.12±4.25),(32.45±4.56),(62.54±7.24),(17.36±2.54)和(52.12±6.35)pg·m L-1,CD3+分别为(66.45±6.74)%,(38.52±4.56)%,(50.32±5.23)%,(21.32±3.24)%和(44.12±4.65)%,CD4+分别为(42.36±5.12)%,(26.02±3.54)%,(34.12±4.21)%,(20.42±3.25)%和(30.25±3.45)%,CD4+/CD8+比率分别为(1.83±0.32),(0.83±0.14),(1.36±0.30),(0.54±0.10)和(1.06±0.22),血清中VEGF分别为(10.42±1.24),(33.45±4.32),(23.36±2.45),(28.12±3.25)和(20.12±2.32)pg·m L-1,肿瘤组织中VEGF分别为(0.21±0.06),(1.04±0.21),(0.51±0.10),(0.76±0.12)和(0.38±0.05)pg·m L-1,实验A,B,C组的上述指标与模型组比较,差异均有统计学意义(均P<0.05);实验B,C组的上述指标与实验A组比较,差异均有统计学意义(均P<0.05);实验B组的上述指标和实验C组比较,差异均有统计学意义(均P<0.05)。结论贝伐单抗联合顺铂有助于抑制Lewis肺癌荷瘤小鼠瘤体生长,可能与其能够改善免疫功能、降低血管内皮生长因子含量等因素有关。
其他摘要	Objective To investigate the effect of bevacizumab combined with cisplatin on the immune function and vascular endothelial growth factors(VEGF) in the mice of Lewis lung cancer. Methods The healthy BALB /c nude mice were injected with Lewis lung cancer cell at the right subaxillary to establish the mouse model of lung cancer. The successful model mice of lung cancer were randomly divided into model group,test A,B and C groups with 8 cases per group. In addition,8 healthy mice were selected as control group. Control group and model group were given 0.9% NaCl 0.4 mL,intraperitoneal injection,twice a week. Test A,B and C groups were treated with 15 mg·kg~(- 1) bevacizumab,5 mg·kg~(- 1) cisplatin,15 mg·kg~(- 1) bevacizumab + 5 mg·kg~(- 1) cisplatin, intraperitoneal injection,twice a week,respectively. After 2 weeks,all the mice were killed,the blood were collected from eyeball and the tumor tissue were weighted. The tumor inhibition rates,immune functions and the levels of VEGF were compared between five groups. Results After treatment,the inhabitation rates of test A,B and C groups were(46.57 ± 5.45) %,(72.03 ± 8.24) % and(87.47 ± 9.02) % with significant difference between any two groups(all P < 0.05). After treatment,the main indexes in control,model and test A,B,C groups were compared: interleukin - 2 were(37.12 ± 5.24),(15.24 ± 2.36),(26.45 ± 4.45),(7.36 ± 1.02) and(22.32 ± 3.25) pg·mL~(- 1), interleukin - 6 were(125.36 ± 15.24),(54.32 ± 6.32),(86.45 ± 10.12),(24.36 ± 3.45) and(74.36 ± 8.54) pg·mL~(- 1),tumor necrosis factor - α were(80.12 ± 4.25),(32.45 ± 4.56),(62.54 ± 7.24),(17.36 ± 2.54) and(52.12 ± 6.35) pg·mL~(- 1),cluster of differentiation 3(CD3 + ) were(66.45 ± 6.74) %,(38.52 ± 4.56) %,(50.32 ± 5.23) %,(21.32 ± 3.24) % and(44.12 ± 4.65) %,CD4 + were(42.36 ± 5.12) %,(26.02 ± 3.54) %,(34.12 ±4.21) %,(20.42 ±3.25) % and(30.25 ± 3.45) %,CD4 + /CD8 + were(1.83 ± 0.32),(0.83 ± 0.14),(1.36 ± 0.30 ),(0.54 ± 0.10 ) and(1.06 ± 0.22 ),the levels of VEGF in serum were(10.42 ± 1.24 ),(33.45 ±4.32),(23.36 ±2.45),(28.12 ±3.25) and(20.12 ± 2.32) pg·mL~(- 1),the levels of VEGF in tumor tissue were(0.21 ± 0.06),(1.04 ± 0.21),(0.51 ± 0.10),(0.76 ± 0.12) and(0.38 ± 0.05) pg·mL~(- 1). There were significant differences between test A,B,C groups and model group(all P <0.05),between test B,C groups and test A group(all P <0.05),between test A group and test B group(all P < 0.05). Conclusion Bevacizumab combined with cisplatin can inhibit the growth of tumor in the mice of Lewis lung cancer,which may be related to the improvement of immune functions and the decrease of VEGF content.
资助项目	浙江省医药卫生基金资助项目（2011ZDA003）;浙江省医学会临床科研基金A类基金资助项目（2016ZYC-A113）
ISSN	1001-6821
卷号	33 期号:23 页码:2394-2397
DOI	10.13699/j.cnki.1001-6821.2017.23.020
页数	4
收录类别	CNKI ; 北大核心 ; CSCD
学科领域	医药、卫生 ; 药学
URL	查看原文
CSCD记录号	CSCD:6166498
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/38750
专题	其他_附属黄岩医院（台州市第一人民医院）附属第一医院其他_附属慈溪医院（慈溪市人民医院）
作者单位	1.温州医科大学附属黄岩医院血液肿瘤内科; 2.温州医科大学附属慈溪医院肿瘤内科; 3.温州医科大学附属第一医院肿瘤内科
第一作者单位	温州医科大学
推荐引用方式 GB/T 7714	章展,孙益青,唐小万,等. 贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子的影响[J]. 中国临床药理学杂志,2017,33(23):2394-2397.
APA	章展, 孙益青, 唐小万, & 李文峰. (2017). 贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子的影响. 中国临床药理学杂志, 33(23), 2394-2397.
MLA	章展,et al."贝伐单抗联合顺铂对Lewis肺癌荷瘤小鼠免疫功能及血管内皮生长因子的影响".中国临床药理学杂志 33.23(2017):2394-2397.

条目包含的文件		下载所有文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
GLYZ201723020.CAJ（190KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	浏览下载